دورية أكاديمية
أعرض في EDS

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

التفاصيل البيبلوغرافية
العنوان: Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
المؤلفون: Scherer F; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Kurtz DM; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Newman AM; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA., Stehr H; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA., Craig AF; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Esfahani MS; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Lovejoy AF; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA., Chabon JJ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA., Klass DM; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA., Liu CL; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA., Zhou L; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA., Glover C; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Visser BC; Division of Surgical Oncology, Department of Surgery, Stanford University, Stanford, CA 94305, USA., Poultsides GA; Division of Surgical Oncology, Department of Surgery, Stanford University, Stanford, CA 94305, USA., Advani RH; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Maeda LS; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Gupta NK; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Levy R; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Ohgami RS; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Kunder CA; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Diehn M; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA. arasha@stanford.edu diehn@stanford.edu.; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA., Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA. arasha@stanford.edu diehn@stanford.edu.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
المصدر: Science translational medicine [Sci Transl Med] 2016 Nov 09; Vol. 8 (364), pp. 364ra155.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Association for the Advancement of Science
مواضيع طبية MeSH: Circulating Tumor DNA/*genetics , Lymphoma, B-Cell/*genetics , Lymphoma, Large B-Cell, Diffuse/*genetics, Adult ; Aged ; Aged, 80 and over ; Algorithms ; Biomarkers, Tumor/blood ; Biopsy ; Cell-Free System ; Female ; Genotype ; Humans ; Immunoglobulins/chemistry ; Lymphoma, B-Cell/blood ; Lymphoma, Large B-Cell, Diffuse/blood ; Male ; Middle Aged ; Mutation ; Prognosis ; Recurrence ; Treatment Outcome
مستخلص: Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, the biology underlying these differences is incompletely understood. We hypothesized that characterization of mutational heterogeneity and genomic evolution using circulating tumor DNA (ctDNA) profiling could reveal molecular determinants of adverse outcomes. To address this hypothesis, we applied cancer personalized profiling by deep sequencing (CAPP-Seq) analysis to tumor biopsies and cell-free DNA samples from 92 lymphoma patients and 24 healthy subjects. At diagnosis, the amount of ctDNA was found to strongly correlate with clinical indices and was independently predictive of patient outcomes. We demonstrate that ctDNA genotyping can classify transcriptionally defined tumor subtypes, including DLBCL cell of origin, directly from plasma. By simultaneously tracking multiple somatic mutations in ctDNA, our approach outperformed immunoglobulin sequencing and radiographic imaging for the detection of minimal residual disease and facilitated noninvasive identification of emergent resistance mutations to targeted therapies. In addition, we identified distinct patterns of clonal evolution distinguishing indolent follicular lymphomas from those that transformed into DLBCL, allowing for potential noninvasive prediction of histological transformation. Collectively, our results demonstrate that ctDNA analysis reveals biological factors that underlie lymphoma clinical outcomes and could facilitate individualized therapy.
(Copyright © 2016, American Association for the Advancement of Science.)
References: J Clin Invest. 2012 Oct;122(10):3424-31. (PMID: 23023713)
Semin Hematol. 2015 Apr;52(2):97-106. (PMID: 25805589)
J Clin Oncol. 2015 Sep 10;33(26):2848-56. (PMID: 26240231)
J Clin Oncol. 2015 Dec 1;33(34):3993-8. (PMID: 26438115)
Blood. 2015 Jan 1;125(1):40-7. (PMID: 25499449)
Cancer Discov. 2014 Sep;4(9):1022-35. (PMID: 25082755)
Cancer J. 2012 Sep-Oct;18(5):411-20. (PMID: 23006945)
J Clin Oncol. 2005 Nov 1;23(31):8122-3; author reply 8123-4. (PMID: 16258114)
J Clin Oncol. 2011 Nov 1;29(31):4079-87. (PMID: 21947824)
Haematologica. 2015 Jul;100(7):e280-4. (PMID: 25749829)
Cell. 2008 Dec 12;135(6):1130-42. (PMID: 19070581)
Blood. 2009 Jun 11;113(24):6069-76. (PMID: 19380866)
Nature. 2000 Feb 3;403(6769):503-11. (PMID: 10676951)
N Engl J Med. 2002 Jun 20;346(25):1937-47. (PMID: 12075054)
J Immunol. 2014 Nov 15;193(10):4888-94. (PMID: 25311808)
Blood. 2015 Jun 11;125(24):3679-87. (PMID: 25887775)
Nature. 2011 Jul 27;476(7360):298-303. (PMID: 21796119)
Expert Rev Mol Diagn. 2015 Jun;15(6):715-9. (PMID: 25773944)
J Clin Oncol. 2013 Aug 10;31(23):2963-9. (PMID: 23835712)
Blood. 2013 Mar 21;121(12):2253-63. (PMID: 23335369)
Nature. 2012 Dec 6;492(7427):108-12. (PMID: 23051747)
Nat Genet. 2008 Jan;40(1):108-12. (PMID: 18066064)
J Clin Oncol. 2011 May 10;29(14):1827-34. (PMID: 21483014)
Sci Transl Med. 2016 Jul 6;8(346):346ra92. (PMID: 27384348)
J Clin Oncol. 2010 Apr 10;28(11):1896-903. (PMID: 20212248)
Blood. 2014 Feb 20;123(8):1214-7. (PMID: 24398326)
Blood. 2013 Aug 15;122(7):1256-65. (PMID: 23699601)
Blood. 2012 Dec 20;120(26):5173-80. (PMID: 23074282)
J Clin Oncol. 2014 Nov 1;32(31):3506-12. (PMID: 25267745)
Blood. 2011 Jun 30;117(26):7070-8. (PMID: 21536860)
N Engl J Med. 2008 Nov 27;359(22):2313-23. (PMID: 19038878)
Nat Med. 2015 Aug;21(8):922-6. (PMID: 26193343)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. (PMID: 18765795)
Nat Genet. 2011 Jul 31;43(9):830-7. (PMID: 21804550)
J Natl Compr Canc Netw. 2016 Feb;14(2):196-231. (PMID: 26850490)
BMC Genomics. 2014 May 28;15:409. (PMID: 24885090)
Br J Haematol. 2014 Sep;166(6):891-901. (PMID: 24943107)
Bioinformatics. 2014 Dec 1;30(23):3390-3. (PMID: 25143292)
Nat Commun. 2016 Jun 10;7:11815. (PMID: 27283993)
J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303. (PMID: 25190696)
N Engl J Med. 2002 Jan 24;346(4):235-42. (PMID: 11807147)
Blood. 2015 Aug 13;126(7):851-7. (PMID: 26105149)
Nat Med. 2014 May;20(5):548-54. (PMID: 24705333)
Leuk Lymphoma. 2015 May;56(5):1213-22. (PMID: 25130477)
Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385)
J Digit Imaging. 2004 Sep;17(3):205-16. (PMID: 15534753)
Genes Chromosomes Cancer. 2016 Mar;55(3):251-67. (PMID: 26608593)
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25. (PMID: 25713363)
Rev Bras Hematol Hemoter. 2013;35(3):189-91. (PMID: 23904809)
J Clin Oncol. 2013 Sep 10;31(26):3272-8. (PMID: 23897955)
PLoS One. 2014 Aug 27;9(8):e105682. (PMID: 25162396)
J Clin Oncol. 2015 Jan 20;33(3):251-7. (PMID: 25135992)
Clin Cancer Res. 2011 Jun 1;17(11):3727-32. (PMID: 21364035)
Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54. (PMID: 17908623)
Cell Rep. 2014 Jan 16;6(1):130-40. (PMID: 24388756)
Hematology Am Soc Hematol Educ Program. 2011;2011:498-505. (PMID: 22160081)
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403. (PMID: 23292937)
Lancet Oncol. 2015 May;16(5):541-9. (PMID: 25842160)
Blood. 2015 Nov 26;126(22):2439-40. (PMID: 26612895)
Nat Genet. 2014 Feb;46(2):176-181. (PMID: 24362818)
J Clin Oncol. 2015 Sep 10;33(26):2835-6. (PMID: 26261249)
Lancet Oncol. 2008 Feb;9(2):105-16. (PMID: 18226581)
Blood. 2003 Sep 15;102(6):1989-96. (PMID: 12676776)
J Clin Oncol. 1993 Dec;11(12):2351-61. (PMID: 8246024)
Blood. 2011 Aug 4;118(5):1350-8. (PMID: 21670469)
Blood. 2000 Mar 1;95(5):1797-803. (PMID: 10688840)
Nat Biotechnol. 2016 May;34(5):547-555. (PMID: 27018799)
Nat Med. 2008 Sep;14(9):985-90. (PMID: 18670422)
Nat Genet. 2010 Feb;42(2):181-5. (PMID: 20081860)
J Clin Oncol. 2000 Feb;18(3):510-18. (PMID: 10653866)
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84. (PMID: 22343534)
Br J Haematol. 2014 Aug;166(3):369-74. (PMID: 24761809)
J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. (PMID: 19509353)
Blood. 2004 Jan 1;103(1):275-82. (PMID: 14504078)
Clin Cancer Res. 2016 Jun 15;22(12):2919-28. (PMID: 26819451)
N Engl J Med. 1993 Sep 30;329(14):987-94. (PMID: 8141877)
J Clin Oncol. 2014 Apr 1;32(10):1066-73. (PMID: 24550425)
N Engl J Med. 2014 Jun 12;370(24):2286-94. (PMID: 24869598)
Blood. 2013 May 30;121(22):4551-4. (PMID: 23476051)
معلومات مُعتمدة: DP2 CA186569 United States CA NCI NIH HHS; CI-71-14 United States DRCRF_ Damon Runyon Cancer Research Foundation; R25 CA180993 United States CA NCI NIH HHS; T32 CA121940 United States CA NCI NIH HHS; U01 CA194389 United States CA NCI NIH HHS; K99 CA187192 United States CA NCI NIH HHS; P30 CA124435 United States CA NCI NIH HHS; R01 CA188298 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Circulating Tumor DNA)
0 (Immunoglobulins)
تواريخ الأحداث: Date Created: 20161111 Date Completed: 20171229 Latest Revision: 20231104
رمز التحديث: 20231104
مُعرف محوري في PubMed: PMC5490494
DOI: 10.1126/scitranslmed.aai8545
PMID: 27831904
قاعدة البيانات: MEDLINE
الوصف
تدمد:1946-6242
DOI:10.1126/scitranslmed.aai8545